Case report: SAF-189s is a potent inhibitor in a lorlatinib-resistant NSCLC patient with acquired compound mutations ALK L1196M and D1203N
Acquired anaplastic lymphoma kinase (ALK) mutation is the major resistant mechanism to ALK tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) patients. At present, treatment options after acquiring secondary ALK mutations are still limited. Here, we report on a patient with meta...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2023-12-01
|
| Collection: | Frontiers in Pharmacology |
| Sujets: | |
| Accès en ligne: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1197163/full |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|